Patients |
Age |
9.42 ± 4.87; 0–17 |
Sex |
57 (51.8%) male |
Race |
Caucasian |
108 (98.2%) |
Non-caucasian |
2 (1.8%) |
Health complications |
CFRD |
5 (4.5%) |
Hemoptysis/pneumothorax |
0 (0.0%) |
Currently on IV antibiotics |
2 (1.8%) |
Listed for lung/liver transplant |
0 (0.0%) |
Health outcomes |
Height (cm) |
142.91 ± 19.26; 100–183 |
Weight (kg) |
39.29 ± 14.56; 17–75.80 |
BMI |
18.47 ± 2.89; 13.51–27.51 |
zBMI |
0.14 ± 0.91; −2.50 to 1.85 |
FEV1% predicted |
94.22 ± 17.79; 38–128 |
Disease severity |
Normal (FEV1% predicted ≥90) |
57 (51.8%) |
Mild (FEV1% predicted 70–89) |
24 (21.8%) |
Moderate (FEV1% predicted 40–69) |
4 (3.6%) |
Severe (FEV1% predicted ≤39) |
1 (0.9%) |
Caregivers |
Age |
37.60 ± 7.78; 21–57 (female) |
|
40.58 ± 5.95; 31–50 (male) |
Sex |
100 females; 22 males |
Race |
Caucasian |
120 (98.4%) |
Non-caucasian |
2 (1.6%) |
Psychological treatment |
Therapy |
10 (10.9%) |
Medication |
30 (31.2%) |
Therapy and medication |
6 (6.0%) |
Number of caregivers with more than 1 child diagnosed with CF |
6 (5.5%) |
HADS scores |
Anxiety |
7.52 ± 4.16 |
Depression |
4.36 ± 4.07 |
CES-D |
11.23 ± 11.49 |